Blinatumomab as a Curative Therapy Option for Relapsed/Refractory Infant Acute Lymphoblastic Leukemia Post-Hematopoietic Stem Cell Transplantation - Case Report
Acute lymphoblastic leukemia (ALL) is the most common type of cancer in children, with a particularly poor prognosis in infants under one year of age. Hematopoietic stem cell transplantation (HSCT) is an effective therapy for relapsed or refractory ALL; however, relapse after HSCT remains a signific...
Saved in:
Main Authors: | Suleimen Zhumatayev (Author), Koray Yalcin (Author), Safiye Suna Celen (Author), Vedat Uygun (Author), Gulsun Karasu (Author), Mehmet Akif Yesilipek (Author) |
---|---|
Format: | Book |
Published: |
The Korean Society of Pediatric Hematology-Oncology,
2024-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Utility of Procalcitonin in the Engraftment Phase of Hematopoietic Stem Cell Transplantation in Children
by: Koray Yalçın, et al.
Published: (2022) -
Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
by: Jiao Xie, et al.
Published: (2023) -
Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis
by: Bin Chen, et al.
Published: (2023) -
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting
by: Alexander Russell-Smith, et al.
Published: (2023) -
Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
by: Songmi Wang, et al.
Published: (2023)